tetano
Editor, Senior Moderator
J Med Virol
. 2021 Jul 27.
doi: 10.1002/jmv.27231. Online ahead of print.
The dynamics of quantitative SARS-CoV-2 anti-spike IgG response to BNT162b2 vaccination
Shun Kaneko[SUP] 1 [/SUP], Masayuki Kurosaki[SUP] 1 [/SUP], Toru Sugiyama[SUP] 2 [/SUP], Yuka Takahashi[SUP] 3 [/SUP], Yoshimi Yamaguchi[SUP] 4 [/SUP], Masayuki Nagasawa[SUP] 5 [/SUP], Namiki Izumi[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The vaccination for SARS-CoV-2 is necessary to overcome coronavirus disease 2019 (COVID-19). However, the time-dependent vaccine-induced immune response is not well known. This study aimed to investigate the dynamics of SARS-CoV-2 anti-spike IgG response.
Methods: The medical staff participants who received two sequential doses of the BNT162b2 vaccination on days 0 and 21 were recruited prospectively from the Musashino Red Cross hospital between March and May 2021. The quantitative anti-spike receptor-binding domain (RBD) IgG antibody responses were measured using the Abbott SARS-CoV-2 IgGII Quant assay (cut off ≥50 AU/mL). A total of 59 participants without past COVID-19 history were continuously tracked with serum samples.
Results: The median age was 41 (22-75) years, and 14 participants were male (23.7%). The median anti-spike RBD IgG and seropositivity rates were 0 (0-31.1) AU/mL, 0.3 (0-39.5) AU/mL, 529.1 (48.3-8711.4) AU/mL, 18836.9 (742.2-57260.4) AU/mL, and 0%, 0%, 98.3%, and 100% on days 0, 3, 14, and 28 after the first vaccination, respectively. The anti-spike RBD IgG levels were significantly increased after day 14 from vaccination (p < 0.001) CONCLUSION: The BNT162b2 vaccination led almost all participants to obtain serum anti-spike RBD IgG 14 days after the first dose. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-Cov-2; mRNA vaccine; quantitative anti-spike RBD IgG.
. 2021 Jul 27.
doi: 10.1002/jmv.27231. Online ahead of print.
The dynamics of quantitative SARS-CoV-2 anti-spike IgG response to BNT162b2 vaccination
Shun Kaneko[SUP] 1 [/SUP], Masayuki Kurosaki[SUP] 1 [/SUP], Toru Sugiyama[SUP] 2 [/SUP], Yuka Takahashi[SUP] 3 [/SUP], Yoshimi Yamaguchi[SUP] 4 [/SUP], Masayuki Nagasawa[SUP] 5 [/SUP], Namiki Izumi[SUP] 1 [/SUP]
Affiliations
- PMID: 34314037
- DOI: 10.1002/jmv.27231
Abstract
Background: The vaccination for SARS-CoV-2 is necessary to overcome coronavirus disease 2019 (COVID-19). However, the time-dependent vaccine-induced immune response is not well known. This study aimed to investigate the dynamics of SARS-CoV-2 anti-spike IgG response.
Methods: The medical staff participants who received two sequential doses of the BNT162b2 vaccination on days 0 and 21 were recruited prospectively from the Musashino Red Cross hospital between March and May 2021. The quantitative anti-spike receptor-binding domain (RBD) IgG antibody responses were measured using the Abbott SARS-CoV-2 IgGII Quant assay (cut off ≥50 AU/mL). A total of 59 participants without past COVID-19 history were continuously tracked with serum samples.
Results: The median age was 41 (22-75) years, and 14 participants were male (23.7%). The median anti-spike RBD IgG and seropositivity rates were 0 (0-31.1) AU/mL, 0.3 (0-39.5) AU/mL, 529.1 (48.3-8711.4) AU/mL, 18836.9 (742.2-57260.4) AU/mL, and 0%, 0%, 98.3%, and 100% on days 0, 3, 14, and 28 after the first vaccination, respectively. The anti-spike RBD IgG levels were significantly increased after day 14 from vaccination (p < 0.001) CONCLUSION: The BNT162b2 vaccination led almost all participants to obtain serum anti-spike RBD IgG 14 days after the first dose. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-Cov-2; mRNA vaccine; quantitative anti-spike RBD IgG.